Skip to main content
PureTech Health plc logo

PureTech Health plc — Investor Relations & Filings

Ticker · PRTC ISIN · GB00BPVG5C82 LEI · 213800LVPDNO2Z9T9I39 IL Manufacturing
Open in API
Filings indexed 1,319 across all filing types
Latest filing 2023-05-10 Transaction in Own Shar…
Country GB United Kingdom
Listing IL PRTC

About PureTech Health plc

https://puretechhealth.com/

PureTech Health is a clinical-stage biotherapeutics company dedicated to discovering, developing, and commercializing new classes of medicine for devastating diseases. The company's research and development engine focuses on advancing novel treatments by enhancing on-target efficacy, improving tolerability, or enabling oral administration of therapeutics with validated mechanisms. Its pipeline includes wholly-owned therapeutic candidates targeting a range of conditions, including idiopathic pulmonary fibrosis, neuropsychiatric disorders, and various cancers.

Recent filings

Filing Released Lang Actions
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement from PureTech Health PLC, dated May 10, 2023. The title explicitly states 'Transaction in Own Shares' and details the purchase of ordinary shares as part of a 'Share Buyback Programme'. This directly corresponds to the definition of a company reporting the purchase or sale of its own shares. Therefore, the correct classification is Transaction in Own Shares (POS).
2023-05-10 English
Vedanta Fast Track Designation & Ph2 Data at DDW
Regulatory Filings Classification · 100% confidence The document is an RNS (Regulatory News Service) announcement from PureTech Health PLC, dated May 9, 2023. It reports on an update concerning its Founded Entity, Vedanta Biosciences, specifically regarding the FDA granting Fast Track designation for drug candidate VE303 and the presentation of Phase 2 data at a medical conference (DDW 2023). The text structure, including the RNS Number, date, and the nature of the announcement (a corporate update on clinical/regulatory progress), strongly indicates a regulatory news release. Since this is a general corporate announcement that doesn't fit the specific categories like Earnings Release (ER), Capital Update (CAP), or Director's Dealing (DIRS), and it is clearly a formal regulatory filing notification, the most appropriate classification is Regulatory Filings (RNS). The document length is substantial (over 17k characters), meaning it is the full announcement, not just a brief notice of publication (which would be RPA).
2023-05-09 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document is an RNS announcement dated May 9, 2023, detailing a 'Transaction in Own Shares' by PureTech Health PLC. It explicitly states the company purchased ordinary shares as part of its Share Buyback Programme, providing transaction dates, volumes, and prices. This directly matches the definition for 'Transaction in Own Shares' (Code: POS). The document is not a full annual report (10-K), an earnings release (ER), or a general management discussion (MDA).
2023-05-09 English
Transaction in Own Shares
Transaction in Own Shares Classification · 100% confidence The document explicitly states the subject matter in the header: "Transaction in Own Shares" and details the purchase of ordinary shares as part of a "Share Buyback Programme." It provides specific transaction dates, volumes, and prices. This directly corresponds to the definition of 'Transaction in Own Shares' (Code: POS). The RNS number and the nature of the announcement confirm it is a regulatory disclosure regarding share capital management.
2023-05-05 English
Akili Trial Results of EndeavorRx in Adults w/ADHD
Earnings Release Classification · 95% confidence The document is a press release dated May 4, 2023, originating from PureTech Health PLC, announcing clinical trial results for its founded entity, Akili, regarding the digital therapeutic EndeavorRx for adults with ADHD. The text details efficacy outcomes (TOVA ACS, ADHD-RS, AAQoL), mentions FDA authorization for a different age group, and states that Akili 'plans to present full data... at a future scientific meeting and will submit the data to the FDA later this year.' This structure—a formal announcement of clinical trial results and future regulatory plans, distributed via RNS (indicated by the RNS Number header)—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since it is a detailed announcement of specific, material operational/clinical news rather than just a summary of financial performance (ER) or a general regulatory notice, and it is not a full report, it fits best as an Earnings Release (ER) if we consider clinical trial results as the primary 'earnings' driver for a clinical-stage company, or RNS as a general regulatory announcement. Given the focus on clinical trial results and FDA submission plans, which are material events, 'ER' (Earnings Release, often used broadly for material operational updates by biotechs) or 'RNS' (Regulatory Filings) are the closest fits. Since it is a detailed announcement of clinical trial results, which often accompanies or substitutes for a traditional earnings release for clinical-stage firms, ER is a strong candidate. However, the presence of the RNS Number header strongly suggests it is being filed as a regulatory disclosure. Given the options, and that it is a specific, material announcement that isn't a full report, 'ER' (Earnings Release, covering operational/clinical milestones) is appropriate, but 'RNS' (Regulatory Filings) is also highly plausible as the distribution mechanism. I will classify it as an Earnings Release (ER) because the core content is the announcement of clinical trial results, which drives investor valuation, similar to financial results. Q2 2023
2023-05-04 English
Transaction in Own Shares
Transaction in Own Shares Classification · 99% confidence The document explicitly states the filing type in the header: 'Transaction in Own Shares'. It details the purchase of ordinary shares as part of a 'Share Buyback Programme' on a specific date (3 May 2023), including volume, price, and individual transaction records. This directly corresponds to the definition of 'Transaction in Own Shares', which maps to the filing code POS (Report of the company buying back or selling its own shares (share repurchase/issuance)). The RNS Number suggests it is a regulatory announcement, but the content is specifically about share repurchase activity, making POS the most precise classification.
2023-05-04 English

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.